Quick answer: microdosing GLP-1 drugs means taking less than the labeled dose of semaglutide or tirzepatide, usually 25% to 50% of the starting dose or spacing doses further apart.[1] No clinical trial has tested this practice. The lowest labeled doses, such as Zepbound 2.5 mg, are for starting treatment and are not approved as maintenance doses.[2] The best-documented risk is dosing errors, which FDA has linked to injections of 5 to 20 times the intended amount from compounded vials.[10]
This guide covers what people mean by the term, what the lowest doses did in trials and what clinicians have published. For background on the drugs, see our semaglutide and tirzepatide profiles and the GLP-1 basics hub.
What “microdosing” a GLP-1 means
There is no medical definition. A 2026 commentary in Expert Opinion on Pharmacotherapy described it as using roughly 25% to 50% of the manufacturer’s recommended starting dose, or stretching the time between doses.[1] People do this in a few ways:
- Click counting: turning a multidose pen’s dial part of the way and counting the clicks to deliver a partial dose.[1][8]
- Extended intervals: taking a dose less often than the label schedule.[1]
- Small draws from vials: drawing a small volume from a compounded multidose vial with a syringe.[9]
Reasons people give include fewer stomach side effects, lower cost and stretching supply.[1] A 2026 nurse-practitioner report also lists wanting to lose a small amount of “vanity weight.”[9]
Is there evidence that it works?
Not from trials designed to test it. The 2026 commentary called high-quality evidence “essentially absent,” with only early reports suggesting less nausea and modest weight loss.[1]
The closest data come from early dose-finding trials, which tested very low doses under controlled conditions:
| Trial | Lowest dose tested | Result at that dose | Placebo |
|---|---|---|---|
| Semaglutide phase 2, obesity, 52 weeks | 0.05 mg daily (0.35 mg per week) | −6.0% body weight | −2.3%[5] |
| Tirzepatide phase 2, type 2 diabetes, 26 weeks | 1 mg weekly | HbA1c −1.06% | −0.06%[6] |
In the semaglutide trial, weight loss rose with dose, to 13.8% at 0.4 mg daily.[5] In the tirzepatide trial, weight change across all four doses ranged from −0.9 kg to −11.3 kg.[6] These were different schedules and populations from how microdosing is practiced today.
The lowest labeled doses are starting doses
Each GLP-1 label starts low and steps up to cut stomach side effects:
| Drug | Labeled starting dose | What the label says about it |
|---|---|---|
| Zepbound / Mounjaro | 2.5 mg weekly | Zepbound: for starting treatment, “not approved as a maintenance dosage”[2][14] |
| Wegovy injection | 0.25 mg weekly | First of four 4-week steps before a 1.7 or 2.4 mg maintenance dose[3] |
| Wegovy tablets | 1.5 mg daily | Maintenance dose is 25 mg daily[3] |
| Rybelsus | 3 mg daily | “Not effective for glycemic control”[4] |
So a “microdose” is usually below doses that the labels treat as warm-up steps. For the full step-up schedules, see the GLP-1 dose conversion chart and semaglutide maintenance dose.
Risks of microdosing
Dosing errors with compounded vials
In July 2024 FDA warned about dosing errors with compounded injectable semaglutide. Patients drew up “five to 20 times” the intended dose from multidose vials, and some providers miscalculated when converting milligrams to units or milliliters. Some people were hospitalized, with reports of vomiting, fainting, dehydration, pancreatitis and gallstones.[10]
A poison-center case series described two people who injected 10 times their intended dose; one had dosed in milliliters and units rather than milligrams.[11] Small, custom doses make this kind of mix-up more likely. If you think you took too much, see semaglutide overdose.
Pen manipulation
Branded pens are built to deliver fixed doses. A 2025 Diabetes Care letter on click counting with semaglutide multidose pens noted that the clicks are unnumbered, that no trials have validated the approach, and that errors “could lead to subtherapeutic effects or increased side effects.”[8] Multidose pens also have use-by limits once opened: the Mounjaro KwikPen must be thrown away after 30 days or 4 weekly doses, even with medicine left.[14] See GLP-1 storage.
Unregulated products
The 2026 nurse-practitioner report warned against “research-grade” peptides, medication sharing and medical-spa products.[9] As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide.[12]
Side effects still happen
Stomach side effects scale with dose but do not vanish. In the tirzepatide phase 2 trial, they affected 23.1% of people at 1 mg, compared with 9.8% on placebo and 66.0% at 15 mg.[6] Every GLP-1 label also carries a boxed warning about thyroid C-cell tumors in rodents, regardless of dose.[2][3]
What clinicians have published
Published views are cautious:
- 2026 commentary: early reports suggest benefits, but evidence “remains limited” and concerns persist around compounded products and dose accuracy.[1]
- 2025 Diabetes Care letter: University of North Carolina clinicians described click counting as a possible option for tolerability or cost with careful patient selection, counseling and monitoring. They noted it is off-label and not endorsed by the manufacturer.[8]
- 2026 nurse-practitioner report: urges clinicians to steer patients away from unsupervised microdosing and unregulated sources.[9]
If you are considering a lower dose
- Talk to your prescriber. Labels let them hold a dose or delay escalation if side effects are a problem; the Zepbound label also allows a lower maintenance dose.[2][3]
- Do not guess conversions between milligrams, milliliters and syringe units.[10]
- If nausea is the reason, see GLP-1 nausea. If cost is the reason, see GLP-1 cost without insurance.
- If you want to taper off, read stopping a GLP-1.
